PATHtoIP LLP’s Post

𝗔𝗿𝗲 𝘆𝗼𝘂 𝗽𝗹𝗮𝗻𝗻𝗶𝗻𝗴 𝘁𝗼 𝗮𝘁𝘁𝗲𝗻𝗱 #𝗖𝗣𝗛𝗜 𝗡𝗼𝗿𝘁𝗵 𝗔𝗺𝗲𝗿𝗶𝗰𝗮 𝗶𝗻 𝗣𝗵𝗶𝗹𝗮𝗱𝗲𝗹𝗽𝗵𝗶𝗮 𝗻𝗲𝘅𝘁 𝗺𝗼𝗻𝘁𝗵? If so, I extend a cordial invitation to meet and explore the possibilities of collaboration. At Pharma Targeting, we specialize in rapidly uncovering your precise target profiles within the pharmaceutical and biotech sectors, even those in Stealth Mode, along with their programs. Our cutting-edge approach allows us to dynamically assess the market in real-time and facilitate direct connections with key decision-makers and companies that have secured funding. By leveraging our services, you can reclaim up to 80% of your valuable time, enabling you to focus on strategic initiatives and capitalizing on opportunities. Partnering with Pharma Targeting offers a genuine First-To-Market advantage. I invite you to discover firsthand how our seasoned team can bolster your commercial endeavours. 𝗦𝗲𝗰𝘂𝗿𝗲 𝗮 𝗰𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗺𝗲 𝗮𝘁 𝗖𝗣𝗛𝗜 𝗯𝘆 𝘀𝗰𝗵𝗲𝗱𝘂𝗹𝗶𝗻𝗴 𝗮 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 𝗵𝗲𝗿𝗲:👉 https://lnkd.in/egt6Xduh #CDMO #pharma #contractmanufacturing #pharma #biotech #drugdevelopment #HPAPI #CMC #pharmamanufacturing #ADC #NCE #biopharma #smallmolecule

We are honored to announce that Dr. Anwar Daud, Managing Director and Chairman of ZIM Laboratories Limited, has been featured in Global Business Reports (GBR) Connect Series. This platform allowed us to share insights into ZIM Labs' growth journey. In this conversation, Dr. Anwar S. Daud delves into emerging trends and challenges that are shaping the future of the Pharma sector. He also highlights ZIM Labs' unique approach to pharmaceutical innovation, showcasing our commitment to driving positive change and delivering cutting-edge solutions to meet the evolving needs of the industry and our customers. Read the full interview here: https://lnkd.in/d4rJMShG #ExclusiveInterview #IndustryInsights #GBR #GlobalBusinessReports #IndustryInsights #Interview #ZIMLabs #GBRConnect #FutureOfPharma #Insights #PharmaStrategies #PharmaInsights #PharmaInnovation #ConnectSeries #PharmaceuticalIndustry #IndustryInsights

When R&D giants sneeze, clinical trials suffer. It’s a well-known fact that the #Pharma sector is among the most R&D intensive industries in the world, with massive investments in #Innovation. Based on quarterly reporting, however, we can see an overall drop in R&D spending between the first halves of 2023 and 2024 (with some companies hit harder than others). As a result, clinical trials are also declining, particularly in European countries. Key findings: - 🚨 12.9% global decrease in R&D spending - 🚨 Overall decline in all countries, including: -30.9% decrease in EU5 region  -22.9% decrease in Canada Reasons behind this decline in R&D go beyond cyclical investment trades. They also include more systemic issues, likely influenced by national policy decisions impacting the pharmaceutical sector. Countries and patients should take note of these issues to right the ship. #Research #ClinicalTrials #Pfizer #JnJ #Abbvie #Merck #Sanofi #Roche #GSK #AstraZeneca #Novartis #BMS Meir Pugatch Pugatch Consilium

When R&D giants sneeze, clinical trials suffer.  It’s a well-known fact that the #Pharma sector is among the most R&D intensive industries in the world, with massive investments in #Innovation. Based on quarterly reporting, however, we can see an overall drop in R&D spending between the first halves of 2023 and 2024 (with some companies hit harder than others). As a result, clinical trials are also declining, particularly in European countries.  Key findings: 🚨 12.9% global decrease in R&D spending 🚨 Overall decline in all countries, including: 30.9% decrease in EU5 region 22.9% decrease in Canada. Reasons behind this decline in R&D go beyond cyclical investment trades. They also include more systemic issues, likely influenced by national policy decisions impacting the pharmaceutical sector. Countries and patients should take note of these issues to right the ship.  #Research #ClinicalTrials #Pfizer #JnJ #Abbvie #Merck #Sanofi #Roche #GSK #AstraZeneca #Novartis #BMS Gabin Nathan

Life Science Business: $300B 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲! The pharmaceutical landscape is evolving as nearly 200 drugs, including 69 blockbusters (annual sales >$1B), approach patent expiration. While this "patent cliff" poses challenges, it also unlocks a $300B market opportunity for those ready to innovate and adapt. 𝐓𝐡𝐞 𝐑𝐨𝐚𝐝 𝐀𝐡𝐞𝐚𝐝 1:- 2025-2029: Blockbusters like Perjeta, Blincyto, Keytruda, and Darzalex will see biosimilar entries, paving the way for increased access and competition. 𝐇𝐨𝐰 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐂𝐚𝐧 𝐒𝐮𝐜𝐜𝐞𝐞𝐝 Digital Innovate: Develop cutting-edge therapies and expand into new markets through digital transformation. Collaborate: Partner strategically for biosimilar launches and market entry. Diversify: Broaden portfolios to create growth opportunities. 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐈𝐦𝐩𝐚𝐜𝐭 𝐟𝐨𝐫 𝐀𝐥𝐥 Patients and providers can benefit from greater treatment options at more affordable prices, while biosimilar manufacturers and innovators can redefine therapeutic landscapes. The future is bright for those who embrace the digital transformation. Let’s shape it together and reach us for AI solutions demonstrations on #clinicaltrialsautomation, #DataHarmonization, #RealworldEvidence #LiteratureReviews etc. Source: Joanna Sadowska

🎯 "We went all in with Systech. Their technology, experience and knowledge of the pharmaceutical market makes them an excellent partner." Rick Seibert, CIO Sharp Services. Learn more 👉 https://lnkd.in/epxvFxAn Learn how Systech partnered with Sharp Services to efficiently manage exceptions and rework to provide operational efficiency. #supplychain #technology #traceability #pharma #innovation #supplychainmanagement #regulatorycompliance #pharmaceuticalmanufacturing #patientsafety #smartpackaging #casestudies #clientsuccess Jim Waters Adam Robinson Brittany Santiago Adam Bartlett Joan Leka Carl-Rainer Stetter Remi Turbet Delof Paulo Machado Lou Ann Hodges Stephen Melander Chris (CJ) Hatt Renee B. Christine G.

Really interesting to see how this landscape will change in the coming years.

RCG Intel supports biopharma companies to craft winning strategies! Connect with Drew Fussner, MBA at PHARMA CI USA next week to create a plan for elevating your strategy. #PharmaCI2024 #Biopharma #StrategicPartner #RCGIntel #CompetitiveIntelligence #Biosimilars #StrategyConsulting #Consulting #PharmaConsulting

SPONSOR SPOTLIGHT SOFE would like to thank Examination Resources, LLC for being a platinum sponsor for the 2024 CDS. Please visit the Examination Resources, LLC booth for more information between sessions and during breaks. CDS Session: Monday, July 29th (B6) The Interesting LOBs: Unique Characteristics of Certain P&C Lines Tuesday, July 30th (C7) Work Paper Documentation: Pros and Cons of Differing Methodologies (C16) Updated IT Exam Considerations - Virtualization and Use of Cloud-Based Solution Providers (C18) Understanding how PBMs affect the pharmaceutical drug supply chain through vertical integration, lack of transparency, and hidden cash flows. Wednesday, July 31st (D9) Exhibit V Best Practices & Case Studies #SOFEonRoute66